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ILLUSTRATIVE CLUSTER OF INFECTION
During the last quarter of 1995 and into 1996 the pro-
portion of serious infection with Streptococcus pyogenes
caused by strains of M type 1 increased markedly in
England and Wales, and small clusters of infection were
reported from several parts of the country; in one of
these [1], the following details were noted. Nine
patients were detected with serious S. pyogenes infection
in a geographic area measuring 20 x 35 km in the
Pennine Dales ofNorthern England during a period of
7 weeks in the winter of 1995/6. In a local population
of approximately 120 000, this gave an incidence
equivalent to 56 cases per 100 000 population per year.
The first detected infection featured rapidly fatal
septicemia with diarrhea, vomiting and grossly elevated
serum creatine phosphokinase enzymes in a 71-year-
old woman. Then a young mother developed necro-
tizing fasciitis of the perineum and lower genital tract,
peritonitis and septicemia after forceps delivery, while
her baby suffered an infected scalp wound, septicemia
and purpuric, desquamating rash. This was followed by
three separate rapidly fatal infections in previously
healthy young people (male 10 years, male 30 years,
female 32 years) featuring pneumonia and septicemia,
and then a fatal case of necrotizing fasciitis and myositis
occurred, affecting the hand and arm of an 86-year-
old woman. There was also a 62-year-old man with
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erysipelas on the face with acute orbital cellulitis and
formation of an anterior compartment abscess, and a
63-year-old woman with erysipelas in a chronically
lymphedematous arm, following a cut to her finger. Of
the five (56%) who died, three succumbed very rapidly,
before reaching hospital. With the exception of the
mother-and-baby pair, there were no known links
between any of the patients.
Typing of eight of nine of these isolates of S.
pyogenes at the Central Public Health Laboratory,
Colindale showed seven with an apparently identical
strain of M type 1 and one of M type 3. Prior to
this cluster, the most recently recorded patients with
invasive S. pyogenes infections of M types 1 and 3 in
the area occurred, respectively, 6 years and 1 year
beforehand. In the 6 months following the cluster there
were two further S. pyogenes infections, one with
necrotizing fasciitis of the leg (M type 3) and one with
tubo-ovarian abscess and septicemia (M type 1).
DISCUSSION POINTS
S. pyogenes is widespread and common and capable
of producing a variety of conditions in humans,
ranging from asymptomatic colonization, simple local
infections, invasion and intoxication to post-infective,
immune-mediated diseases. An increased occurrence of
severe forms of S. pyogenes infection has been detected
in many parts of the world in recent years [2,3J, most
commonly featuring M types 1 and 3 [4,5J. Much
public interest and concern has arisen following
widespread publicity of certain outbreaks, clusters and
even individual infections, such as those occurring in
well-known people from the realms of politics and
entertainment [6-9].
The cluster of S. pyogenes infection in Gloucester-
shire, UK in 1994 [6], unusual in that it featured an
almost uninterrupted run of cases of necrotizing
fasciitis, and others such as in Nairn, Scotland [10] and
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in a valley of South Wales [11], yielded multiple M
serotypes of S. pyogenes. These episodes appear to be
more than chance events but no good explanation for
their occurrence has yet been found; various hypo-
theses have been proposed, including the known
possibility of horizontal exchange of type- or viru-
lence-determining genes between strains [12] and of
viral or other cofactors causing a temporary enhanced
susceptibility to streptococcal infection in the com-
munity [6]. In contrast, the cluster described here was
largely caused by a single strain of M type 1 highly
prevalent in the UK at the time and probably identical
to a virulent clone (ET1, RFLP pattern la) identified
from recent serious infections worldwide [12J. Un-
recognized cofactors might also have played a part in
precipitating this striking and very brief local episode.
Figures for the incidence of diagnosed invasive S.
pyogenes infection are known to vary according to the
completeness of surveillance and reporting [13], the
case definitions employed and the temporal and
geographic confines selected for study; figures can also
be influenced by the age and ethnicity of the patients
[14]. A state-wide incidence from Ontario in 1991 of
0.3 cases/l00 000 population/year [13] contrasted with
regional and national reported bacteremia rates from
various countries of between 1.8 and 4.3 [14,15]. The
local incidence rate for invasive infection over the 14
weeks of the Gloucestershire cluster [6J was equivalent
to 8.1/100000/year, while in one county in the
Norwegian outbreak of 1988 [8] an incidence rate of
11 was reached. In comparison, figures for the recent
UK community-based clusters in the Isle ofWight [1],
South Wales [11] and the Pennines (as described here)
were very high at 33, 42 and 56 respectively.
The variety of diseases seen in the cluster recounted
here resembled cases described in recent outbreaks also
caused by M type 1 S. pyogenes in Sweden, Norway and
Denmark [15-17]. It is intriguing that a single strain of
Streptococcus can produce such a variety of forms of
serious disease in individuals, seemingly striking at
random in a community; this generally occurs against
a background offrequent transmission and minor forms
of infection that pass with little investigation and note.
We have only a scanty understanding of the deter-
minants of disease occurrence and pattern in the
individual case but, in addition to the pathogenic
properties of the particular organism involved, the
following are likely to be important: rate of passage of
the organism before the encounter, inoculum size,
portal of entry, cofactors (as above), delay before
specific antimicrobial treatment is given, the state of
prior immunity to the organism and its toxins [2] and




In each if the numbered questions, at least one, and up to Jive,
if the individual entries are correct. (The answers are at the
end of this article.)
1. S. pyogenes
a) Is never found in animals. True/False
b) Is the only Streptococcus species
that reacts with anti-Lancefield
group A antiserum. True/False
c) Shows very little clonal diversity
within M types. True/False
d) May fail to respond to penicillin
given in conventional doses. True/False
e) Shows a significant reduction in
expression of surface virulence
factors and secreted protein products
when treated with clindamycin. True/False
2. Invasive S. pyogenes disease
a) Occurs with increased frequency in
patients with chicken pox or measles. True/False
b) Most frequently originates from a
skin/soft tissue focus of infection. True/False
c) Most commonly involves high-
number M type 'skin' strains of
S. pyogenes. True/False
d) Features diarrhea and/or vomiting
in up to 30% of patients. True/False
e) Rarely leads to metastatic foci of
infection. True/False
3. Streptococcal necrotizing fasciitis
a) Frequently involves S. pyogenes in
pure culture. True/False
b) Is caused by organisms from a
limited number of 'necrogenic'
M types. True/False
c) Is an indication for hyperbaric oxygen
therapy. True/False
d) Often requires amputation if it affects
a limb. True/False
e) Carries a mortality rate of
approximately 40%. True/False
4. Patients with streptococcal toxic
shock syndrome
a) Usually feature a typical scarlet
fever rash. True/False
b) Frequently give a history of taking
non-steroidal anti-inflammatory drugs
(NSAIDs) around the time of onset of
illness. True/False






from domestic and laboratory animals, including
dogs, cats, cows, monkeys, mice and toads [19]. Un-
pasteurized milk-borne outbreaks of human sore
throat, accompanied in some cases by scarlet fever or
erysipelas, were reported in early years as a result of
bovine mastitis with S. pyogenes acquired from handlers
in the milking parlor. M type 50 S. pyogenes appears to
produce a natural infection in mice. Persistent infection
with S. pyogenes in families is sometimes associated with
respiratory carriage in the household pets.
In addition to S. pyogenes, occasional strains of
S. anginosus ('milleri'), S. equisimilis [20] and non-
hemolytic streptococci such as S. salivarius will react
with LancefIeld group A antisera. Because of their
colonial and other features, these organisms only rarely
cause confusion in the laboratory identifIcation of S.
pyogenes and, for most practical purposes, the expression
'group A Streptococcus' (GAS) is conveniently and
reason-ably used as a synonym for S. pyogenes.
The typing system for S. pyogenes based on sero-
logic differences in surface M-protein antigen has been
in regular use for more than half a century. Insofar as it
relates to a major virulence factor and M-protein
usually occurs in a single, stable and easily detected
form in an organism, this has proved very useful for
clinical purposes, epidemiology and general classifIca-
tion [21]. Recent molecular biological and genetic
research has shown considerable clonal (,strain') diversity
in streptococci ofcertain commonly occurring M types
and an ability for horizontal transfer of genes encoding
M-proteins to occur between strains [12,22,23]. This
insight suggests that we should re-evaluate the con-
ventional view that an M type somehow represents a
distinctive and homogeneous cell line ofStreptococcus,
although in a particular outbreak it may do so, and
recognize that large interclonal variation in virulence
and disease association can occur within an M type.
S. pyogenes is generally extremely sensitive to
penicillin, and so far no strain has been isolated from
clinical specimens showing a decreased susceptibility to
the drug. Most group A streptococcal infections in the
upper respiratory tract or skin or soft tissues can
therefore easily be treated with penicillin. Despite this
sustained exquisite susceptibility to the drug, it has been
known for some years that there is a tangible failure rate
for primary penicillin treatment of S. pyogenes in the
tonsils and pharynx [24,25], with higher failure rates on
retreatment. This may have several explanations but, in
particular, it is thought to be often due to the presence
and selection of other organisms that can protect the
streptococci by mechanisms such as ~-lactamase
production. Penicillin tolerance (i.e. a clear discrepancy
between inhibitory and bactericidal effects of the drug)
has been shown in some isolates of S. pyogenes in this
Question 1
Although S. pyogenes is highly adapted to its one natural
host, the human, it has been cultured from time to time
7. Acute rheumatic fever
a) Has been in steady decline in developed
countries during the last 40 years. True/False
b) Is frequently associated with mucoid
strains of S. pyogenes. True/False
c) Is caused by a restricted number of
M types, usually different from those
associated with post-streptococcal
glomerulonephritis. True/False
d) Is rarely seen in combination with
acute post-streptococcal nephritis in
a patient. True/False
e) Patients almost always give a history
of preceding sore throat. True/False
COMMENTS
6. Acute post-streptococcal glomerulonephritis
a) Is restricted to patients with upper
respiratory tract infection. True/False
b) In tropical areas is often associated
with the epidemiology of scabies. True/False
c) Can usually be prevented by
appropriate antibiotic treatment given
up to 4 days from onset of infection. True/False
d) Is thought to be associated with
streptokinase enzymes. True/False
e) Occurs only after infection with
S. pyogenes. True/False
5. Streptococcal pyrogenic exotoxin A (SPE A)
a) Enhances cellular production of
tumor necrosis factor.
b) Shows approximately 30% structural
homology with staphylococcal
enterotoxin B.
c) Is encoded by a gene on a
Streptococcus-infecting bacteriophage.
d) Is a superantigen.
e) Is, like SPE B, a proteinase enzyme
precursor.
c) Are likely to have pre-existing
high levels of antistreptococcal pyrogenic
exotoxin antibodies. True/False
d) Almost invariably show detectable
bacteremia. True/False
e) May show a profound fall in counts
of circulating polymorphonuclear
leukocytes and/or lymphocytes. True/False
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setting but it is uncertain whether it plays a part in
treatment failure [26]. Attempts to eradicate strepto-
cocci from the pharynx with antibiotics appear to
be less successful in carriage than in acute infection
[27].
A further important limitation on the efficacy of
penicillin is in invasive S. pyogenes infections such as
necrotizing fasciitis and septic shock where, despite the
use ofvery high doses, clinical response can still be slow
and unsatisfactory. It has therefore been suggested that,
for example, clindamycin, which directly interferes
with the protein synthesis in streptococci, even in the
stationary phase of growth [2], should be used. In
addition to producing a reduction in expression of
surface capsule and M-protein, this will cause an
immediate cessation of the release of the streptococcal
pyrogenic exotoxins which, as superantigens, induce
release ofa cascade ofcytokines that form an integrated
part of the pathogenesis of these diseases. This concept
has been confirmed in an experimental mouse model
of streptococcal infection [28-30]. Initial clinical results
with clindamycin in this setting, either alone or in
combination with penicillin, have been promising
but the therapy still awaits formal assessment in a
prospective clinical trial.
Ouestion 2
Serious streptococcal infections sometimes occur in
patients with acute viral infections, and associations
with varicella, measles and enteroviruses have been
noted with most regularity [13,31,32]. The majority of
published case series reports of S. pyogenes bacteremia
feature some patients with chicken pox, and it is
thought that a temporary immune suppression induced
by the virus might be relevant in addition to the lesions,
which provide a portal of entry. Respiratory infections
with measles and influenza viruses are thought to
predispose the patient to bacterial pneumonia (such as
with Staphylococcus aureus and S. pyogenes) by various
mechanisms, including damage to the respiratory
epithelium and promotion of bacterial adherence,
multiplication and invasion. The coughing caused by
respiratory virus infection is also likely to promote
transmission of bacterial pathogens, such as S. pyogenes,
harbored in the pharynx.
Studies of invasive S. pyogenes infection have
repeatedly shown skin and soft tissues to be the main
portals of entry to the body [2,13-15,33]; local lesions
associated with bacteremia include infected cuts and
burns (sometimes with associated ascending lymph-
angitis and regional lymphadenitis), erysipelas, cellulitis,
infection from intravenous drug abuse and necrotizing
fasciitis. Other portals of entry include the upper
respiratory, genital and gastrointestinal tracts, but in a
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minority of patients the origin of bacteremic infection
remains obscure.
Superficial pyoderma lesions are often caused by
'skin' strains of S. pyogenes, characterized by complex
T-antigen types and by high-number or newly recog-
nized 'provisional' M types [34], but in general these
streptococci show little tendency to invade the body
more deeply. The predominant organisms circulating in
communities, those found most frequently in throat
infections, scarlet fever and wound, deep soft tissue and
bacteremic infections, are mainly of the lower-number
M types [35], although the particular strains involved
vary from time to time and place to place [4,5].
Commonly, strains of S. pyogenes M types 1 and 3 are
rich in surface M-protein and these types occur with a
high frequency in invasive infections [4,5,35].
Symptoms of diarrhea and/or vomiting occur in
up to a third of patients, both with the streptococcal
toxic shock syndrome [14,15,361 and with other forms
of invasive S. pyogenes infection [37], sometimes
misleading clinicians into making an initial diagnosis of
gastroenteritis. The mechanisms by which infection
might produce these effects have not been clarified. S.
pyogenes will sometimes pass down the intestines from
a focus in the respiratory tract to be found in the feces,
but the organism is not known to be a direct cause of
gastroenteritis. Possibly, these symptoms in severe
infection represent a form of 'organ intoxication', or
the triggering of a defense mechanism intended to rid
the body of offending pathogens.
Aggressive local infection with S. pyogenes can lead
to direct extension into adjoining organs and planes in
the body, such as spread from the female genital tract
to produce peritonitis. Once uncontrolled infection has
gained access to the bloodstream, there is a substantial
risk that metastatic lesions will develop, such as septic
arthritis, osteomyelitis, pyomyositis, abscess, menin-
gitis, endophthalmitis and acute endocarditis [2,38,39].
Published case series of patients with S. pyogenes
bacteremia attest to the frequency of these various
complications, which may be established already at
clinical presentation, develop during the first few days
of management or show at post-mortem examination
[2,7,15,16,37]. As an example, preliminary analysis of
the ongoing enhanced surveillance study of invasive
S. pyogertes infection in England and Wales [33] showed
septic arthritis in 6.9% of reported cases and meningitis
in 2.3%.
Ouestion 3
A detailed study of the microbiology of necrotizing
fasciitis (NF) [40] showed two patterns: type I, in
which combinations of a wide variety of bacteria
occurred, including anaerobes, Enterobacteriaceae
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and non-group A streptococci; and type II, yielding
S. pyogenes with or without other organisms such
as Staphylococcus aureus. This classification has been
generally accepted and confirmed in subsequent
studies. S. pyogenes appears to be unique in that it has
the ability to produce NF in pure culture [40-42). It is
often impossible to distinguish the microbial etiology
(i.e. types I or II) on clinical grounds alone, although
the presence of signs of the toxic shock syndrome in a
case suggests streptococcal infection.
Isolates of S. pyogenes from cases of NF show a
variety of M types, reflecting the overall distribution of
serotypes in invasive streptococcal disease [6,33,42]; in
recent years this has included aggressive strains of M
types 1 and 3 in many parts of the world. It is not
thought that any particular M type has specific
'necrogenic' properties. In one study [43] a higher
production ofproteinase enzymes was found in isolates
from NF patients than from others, but this finding has
not been confirmed by other investigators.
The necrosis of overlying tissues in NF is largely
the result of thrombosis of subcutaneous vessels
associated with active infection in the superficial fascia.
If is doubtful whether this process would be influenced
significantly by hyperbaric oxygen therapy, and research
to date has shown no clear benefit from this treatment
in streptococcal NF [44-46]. Possible delays to surgery
(which, together with systems support and anti-
microbial therapy, is the definitive treatment in this
disease) and difficulties with inter-hospital transfer ofan
acutely ill patient can make hyperbaric oxygen therapy
a risky option to pursue. However, if this is easily
available and the patient is known or highly likely
to have type I disease with a significant anaerobic
component to the infection, as is often the case m
cervical NF [47], there may be stronger reasons to
employ it.
Surgery involves early and repeated radical excision
of necrotic skin, fat and superficial fascia [42,45].
Muscle is not usually infected or necrotic, and ampu-
tation of limbs can usually be avoided, although digits
are sometimes lost. Serum creatine phosphokinase
enzymes are frequently raised in patients with strepto-
coccal NF [2,42,48], indicating damage to muscle
fibers, but this may be due to the effects of circulating
streptococcal toxins or ischemia from edema and raised
compartment pressures; this finding should be inter-
preted with caution and not assumed to be evidence of
pyomyositis or muscle necrosis.
The mortality rate in streptococcal NF varies in
different reports from 9% to 63% [2,41,42,48] depend-
ing on the age and previous state of health of the
patient, the location and extent of the lesions and the
speed and adequacy of treatment. In a meta-analysis of
146 patients with NF (bacteriologic types I plus II) the
collective mortality rate was 38% [44]. With prompt
recognition of the disease (which can be difficult in the
early stages) and a preparedness of the staff to be
'bloody, bold and resolute' [42,45] the high case-fatality
rate can be significantly reduced.
Question 4
The streptococcal toxic shock syndrome (TSS) has
been widely reported since its first description in 1987.
The defmition of this syndrome [49] requires isolation
of S. pyogenes together with clinical signs of severity
including hypotension and at least two ofthe following:
renal impairment, coagulopathy, liver involvement,
adult respiratory distress syndrome, diffuse capillary
leak, generalized erythematous macular rash and soft
tissue necrosis. A review of 59 published cases of
streptococcal TSS [50] showed that rash was reported
in 81 % of patients, with desquamation in 41%, but
detailed accounts [2,14,36] showed that many were
petechial or maculopapular in nature and few were
typical of scarlet fever. Streptococcal pyrogenic
exotoxins (SPEs) are thought to play important roles in
this disease [9,43] but the rashes they can induce,
including that of scarlet fever, are considered to be
minor manifestations in comparison with their
powerful systemic effects.
Many patients with streptococcal TSS, and with
NF, give a history of taking non-steroidal anti-inflam-
matory drugs (NSAIDs) at or around the time of onset
or development of their disease [2,51-53]. The
modes of action of NSAIDs vary between different
classes of the drugs but, in general, they result in
profound inhibitory effects on the acute inflammatory
reaction, with enhanced cytokine production and
dose-dependent inhibition of polymorphonuclear
leukocyte functions. These effects, and the delay in
presentation brought about by partial relief of symp-
toms, are likely to be significant for the spread of
infection and intoxication by streptococci. Definitive
studies to investigate possible causes and effects of these
drugs, infection and intoxication in vivo are awaited.
Three streptococcal pyrogenic exotoxins, SPE A,
Band C, have been known and studied for years;
recently, two further mitogens, SPE F and SSA, have
been isolated and reported to have superantigenic
activities similar to those of the earlier toxins [54,55].
As for SPE B, the production ofthese toxins varies with
the strain and is not supposed to be phage encoded. In
larger studies it has been found that the toxin pattern
as well as the amount of these five toxins is highly
variable among different isolates, which may partly
account for the variable outcome of the streptococcal
infection in patients. However, the host factor in
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infection is also of utmost importance. Current
hypotheses on the mechanisms of shock and tissue!
organ damage in streptococcal TSS [2] include the
concept that these effects will be most severe in patients
who lack antibody to the particular SPEs elaborated by
the infecting streptococci. This view is consistent
with the epidemiologic observation that in invasive
forms of S. pyogenes infection streptococcal TSS occurs
disproportionately in previously healthy children and
young adults, who might not yet have been exposed
sufficiently to SPE antigens. Support for this concept
comes from serologic studies of patients, showing
that those who developed a serious, sometimes lethal
infection lacked neutralizing antibodies to one or
several of these toxins [23,56]. Furthermore, ordinary
polyvalent y-globulin preparations have a protective
effect in diseased patients related to the content of
toxin-neutralizing antibodies, a fact which has been
used therapeutically [57,58]. Thus, not only the
toxigenic capacity of the invasive strain but also the
immune status of the host is decisive for the outcome
of the disease. It can be added that there is an individual
reactivity of the host to the toxins, as the affinity of the
V-~ region of the T-cell receptor varies in relation to
the V-~ profile of the toxins [59].
Although streptococcal TSS is usually associated
with an invasive form of infection it has been reported
as a systemic manifestation of local streptococcal
infection. In an early detailed report [60], two of three
patients, with cellulitis and myositis, showed repeatedly
negative blood cultures; in a subsequent review of 59
patients [50], bacteremia was documented in only 34
(58%1). Failure to detect bacteremia can be due to
absence of organisms from the bloodstream at the time
of sampling or result from blood being drawn after
antimicrobial drugs have been given, or from a failure
to take blood cultures at all; reports suggest that the
majority of patients with streptococcal TSS, but by no
means all, do have detectable bacteremia.
Hematologic findings in streptococcal TSS and NF
are variable, with most patients showing a normal total
white blood cell count or a mild leukocytosis with a
pronounced left shift (i.e. presence of immature cells)
[2,7,36]. Occasional patients show neutropenia, which
appears to be associated with poor clinical outcome,
although the number ofcases reported with this pattern
so far has been small [15,16,42]. In a series of patients
with invasive S. pyogenes infection [7], 11 of 14 with a
normal or elevated white blood cell count showed
lymphopenia «1000 cells!mm3) and it was suggested
that this might represent local endothelial recruitment
and pooling of the cells at sites of infection, perhaps




SPEs, formerly known as erythrogenic or scarlet fever
toxins, may be elaborated singly or in combination by
particular strains of S. pyogenes. SPE A, Band C have
been well characterized [9,61] and further toxins and
molecular variants in this series are now being reported.
SPE A in particular has been noted as an important
product of the isolates of S. pyogenes in the resurgence
of severe forms of infection and TSS in the USA and
elsewhere since the late 1980s [9,36,43], although in
Europe production of toxins Band C has been a
dominant feature in many of the isolates from such
disease [23,56].
The biological activities ofSPE A include enhance-
ment of susceptibility to Gram-negative endotoxin
shock, stimulation of macrophages to produce tumor
necrosis factor (a mediator thought to be of special
importance in the induction of shock and organ failure
[62]), pyrogenicity, cytotoxicity for various tissues, in-
cluding the heart, depression of the clearance function
of the reticuloendothelial system, alteration of the
blood-brain barrier, mitogenicity for T-cells and
suppression of B-lymphocyte timction. SPE A shows
approximately 30% structural homology with staphyl-
ococcal enterotoxin B, one of the principal staphyl-
ococcal toxins associated with TSS. The gene for
production of SPE A is located on the temperate
bacteriophage T12. The gene encoding SPE C is also
associated with bacteriophage, and the toxin shows
some structural and functional similarity to SPE A,
although it is a larger molecule and less immunogenic.
Many of the powerful effects of these two toxins
are thought to be associated with their function as
superantigens, i.e. they have the ability to bind to the
MHC class II molecules of the antigen-presenting cells
and to the V-~ chains ofT-cell receptors in such a way
as to recruit far larger numbers of cells than would
occur in conventional, specific antigen presentation
[63,64]. SPE B has a different mucture, being secreted
as a zymogen ('streptococcal proteinase precursor') and
converted to a proteinase with biological functions
including pyrogenicity, plasmin binding and cyto-
toxicity. The gene for SPE B is thought to be present
in all isolates of S. pyogenes although, as with other
SPEs, the amounts of toxin produced by the bacteria
vary from strain to strain and according to cultural
(environmental) conditions.
Ouestion 6
Post-streptococcal glomerulonephritis (PSGN) is not
restricted to patients with S. pyogenes upper respiratory
tract infection (URTI) but can occur following
infections in other parts of the body, most notably the
skin. For patients with pyoderma-associated PSGN
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there is, in comparison with URTI-associated nephritis,
a higher attack rate in S. pyogenes-infected individuals
(up to 15% in outbreaks that feature the complication),
a younger age of patient (often less than 6 years), a
longer latent period before onset ofdisease (commonly
18-21 days compared with about 10 days after URTI)
and a seasonal peak related to the pyoderma season
(summer and autumn as compared with winter and
spring for URTI) [65].
Streptococcal pyoderma follows implantation of
organisms into the superficial layers of the skin,
potentiated by various forms of minor trauma. Scabies
and insect bite-induced excoriation of the skin are very
frequent precipitating factors for this infection and for
PSGN in many parts of the world, and this whole
complex of disease is amenable to scabies control
programs [34,66,67].
Currently, most cases of PSGN in the developed
countries of the world are sporadic and associated with
throat infections usually caused by S. pyogenes M type
12, although other types are isolated from time to time,
such as 1, 4, 6 and 25. In contrast, skin-associated
PSGN is often of the epidemic form and caused by
streptococci ofM types 49, 53, 55, 56, 57 and 60 [68].
The endemic appearance of PSGN has been reported
from Trinidad, where a succession of new types has
been traced in the population [69]. Although certain
M types of S. pyogenes have developed a reputation as
'nephritogenic', the disease is more strongly associated
with certain strains within the types. Recent epidemics
with previously classic 'nephritogenic' serotypes such
as M type 49 in the UK [4,35] and M type 12 in
Japan were not associated with increases in overt
PSGN.
Antibiotic therapy of streptococcal infection com-
menced up to 9 days from onset is usually successful in
preventing acute rheumatic fever but results have been
less impressive for the prevention ofPSGN. One often
quoted study reported a lower rate of hematuria and
nephritis in patients treated with penicillin for M type
12 S. pyogenes URTI than in those given placebo
[70], but others have failed to confirm such effects,
particularly in skin infection [71]. Experimental and
clinical findings suggest that appropriate antibiotic
treatment commenced early (i.e. up to 4 days from
onset of infection) has the potential to prevent PSGN.
The severity of PSGN in the developed countries
seems to be in continuing decline [72]. In contrast, the
disease is still a serious threat in developing countries,
where it is often associated with long-standing or
repeated skin infections. It cannot be ruled out that the
favorable outcome in the developed countries is related
to early treatment of throat infections, while the long-
standing untreated skin infection often gives a high and
long-lasting bacterial burden with continuous release of
the nephritogenic factors.
Research in recent years into the etiology ofPSGN
appears to implicate at least three related streptococcal
protein antigens: (1) nephritis strain-associated protein
(NSAP), which is a variant streptokinase enzyme
('nephrostreptokinase') with an affinity for the
glomerular basement membrane and plasminogen-
activating activity; (2) endostreptosin, which is liberated
on disruption of streptococci and may be the pre-
secreted form ofNSAP; and (3) 'preabsorbing antigen',
which may be a degraded form ofNSAP [73,74]. It has
been proposed that binding of these proteins to the
glomerular basement membrane is followed by in
situ deposition of antibody and complement, with
consequent disturbance of glomerular function. Other
work has shown that SPE B can be detected in the renal
lesions and might playa part [75]. Further research is
underway employing experimental animal models of
PSGN to investigate the roles played by these various
substances.
The incidence of overt PSGN has declined
markedly in developed countries in recent decades
although it remains a common complication in many
other parts of the world. Serologic studies have shown
that most people develop antibodies to NSAp, endo-
streptosin and other streptococcal products following
common streptococcal infections in childhood. The
current low incidence of overt PSGN remains un-
explained but this might be partly due to an inability
of the predominant circulating strains of S. pyogenes to
produce sufficiently large amounts of nephritogenic
products and to patterns of acquired immunity in the
population, perhaps with an increased proportion of
subclinical disease.
An outbreak of S. zooepidemicus infection (a
Lancefield group C zoonosis) following consumption
of poorly pasteurized milk in Romania in 1968 was
followed, in one third of cases, by PSGN. In a similar
outbreak in the UK in 1982 [76] and in reported
sporadic infections with group G streptococci featuring
PSGN [77], the responsible organisms have been shown
to produce endostreptosin or molecular variants of
NSAP. The association of PSGN with non-group A
streptococci, particularly with S. zooepidemicus, suggests
that the disease might occur naturally amongst the wide
variety of animals infected with these organisms-a
suitable area for veterinary research.
Question 7
The incidence of acute rheumatic fever (ARF) has
declined greatly in industrialized countries during this
century, mainly, it is thought, as a result of improved
living standards, better health care for children and the
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widespread use of antibiotics for respiratory tract
infections [78,79], but the disease is still the most
common cause of acquired heart disease in developing
parts of the world. Unexpectedly, a marked resurgence
of ARF occurred in several parts of the USA from the
mid-1980s [80,81], commonly featuring infection
with highly mucoid strains of S. pyogenes [82]. No
comparable change in the epidemiology of ARF was
reported in Europe at this time.
ARF is associated with strains of S. pyogenes within
a limited number of 'rheumatogenic' M types (such as
1, 3, 5, 6, 14, 18, 19 and 24) which frequently show
high levels of hyaluronic acid encapsulation and surface
M-protein, possibly enhanced by rapid passage of the
organisms from patient to patient in the community
[81]. This array of M types shows distinct structural
differences from those associated with nephritis ('neph-
ritogenic' strains) [21] and it is very unusual to
encounter a patient suffering from both complications,
ARF and PSGN.
In addition to the characteristics of the infecting,
virulent streptococci, host factors appear to be of
special importance in the pathogenesis of ARE Attack
rates following URTI with rheumatogenic serotypes of
S. pyogenes are in the order of 2-3% but are higher in
certain families and races, suggesting that hereditary
factors are involved. In patients with previous attacks,
the risk following further episodes of infection is
approximately 50'1'0 [83]. There is a high association of
ARF with certain antigenic markers detectable on B-
lymphocytes and a higher incidence ofdisease in patients
of certain HLA histocompatibility types [81,83].
A feature of the disease in many patients is the
exaggeration of immune responses to many strepto-
cocccal antigens, including antibodies measured for
diagnosis such as anti-streptolysin 0, anti-DNase B,
anti-hyaluronidase and anti-group A carbohydrate
antigen [84]. However, antibody titers are not always
raised above normal levels by the time that serum is
tested from a patient with ARF, especially when there
is a long latent interval from the primary infection (as
in chorea). It should also be noted that a substantial
proportion ofpatients (two thirds in a recent study [80])
give no clearcut history of an antecedent sore throat,
and that cultures from the throat at the stage of ARF
do not always yield S. pyogenes [84].
The etiology of ARF is thought to include auto-
immunity involving both humoral and cell-mediated
components related to known antigenic similarities
which exist between streptococcal components and
various host tissues [83]. A genetically determined brisk
or aberrant immune response to streptococci or their
products may play an important part in this process.
The orthodox view is that ARF occurs exclusively after
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URTI with S. pyogenes; occasional reports have sug-
gested that the disease might occur after skin infection
[85] or with group G streptococci, but available data are
tenuous and there is a need for £luther study.
SUMMARY
Amongst the common bacterial pathogens of humans
there are few that can produce such a varied repertoire
of diseases and such rapid and devastating infection as
can occur, on occasions, with S. pyogenes. Periodic and
unpredictable changes in the dominance of certain
strains circulating in the community bring to vulner-
able populations new risks of virulent attack and
changes in the incidence of specific type-associated
diseases. The recent emergence of streptococcal toxic
shock syndrome, the resurgence of invasive disease and
the reappearance ofacute rheumatic fever in some parts
of the Western world should dispel any complacency
that might have developed about this organism. In the
struggle against S. pyogenes, huge benefits have certainly
accrued from improvements in housing, nutrition,
public health, the availability of antibiotics and the
fruits ofa century of research. Through a long and close
association, S. pyogenes has become finely attuned to
its human host and the relationship is many-sided,
complex and subtle. Accordingly, there is much yet to
be learned about the organism and about humans'
reactions to it. The insights to be gained from the study
of this infection are likely to throw important light onto
broader fields of medicine and infectious diseases.
Answers to the multiple-choice qUllstions
Ql: a. False; b. False; c. False; d. True; e. True
Q2: a. True; b. True; c. False; d. True; e. False
Q3: a. True; b. False; c. False; d. False; e. True
Q4: a. False; b. True; c. False; d. False; e. True
Q5: a. True; b. True; c. True; d. True; e. False
Q6: a. False; b. True; c. True; d. True; e. False
Q7: a. False; b. True; c. True; d. True; e. False
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